(Q35770541)

10 August 2017

1 reference

title

Drotrecogin alfa (activated): a pharmacoeconomic review of its use in severe sepsis (English)

1 reference

10 August 2017

0 references

1 reference

James E Frampton

1

1 reference

PubMed ID

15137883

10 August 2017

Rachel H Foster

series ordinal

2

1 reference

10 August 2017

1 January 2004

1 reference

10 August 2017

1 reference

10 August 2017

22

1 reference

10 August 2017

7

1 reference

10 August 2017

445-476

1 reference

https://scigraph.springernature.com/pub.10.2165/00019053-200422070-00004

10 August 2017

0 references

cites work

Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock

1 reference

12 December 2020

Risk-benefit analysis for drotrecogin alfa (activated).

1 reference

12 December 2020

Drotrecogin alfa (activated): a novel therapeutic strategy for severe sepsis

1 reference

12 December 2020

Recombinant human activated protein C for use in severe sepsis

1 reference

12 December 2020

Economic burden of illness imposed by severe sepsis in Austria

1 reference

12 December 2020

Medicare to partly cover extra cost of sepsis therapy, drug-eluting stents

1 reference

12 December 2020

Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis

1 reference

12 December 2020

A price for cost-effectiveness: implications for recombinant human activated protein C (rhAPC)

1 reference

12 December 2020

Introduction: rationale for using drotrecogin alfa (activated) in patients with severe sepsis

1 reference

12 December 2020

2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference

1 reference

12 December 2020

Recommendations of the Panel on Cost-effectiveness in Health and Medicine

1 reference

12 December 2020

Magnitude and duration of the effect of sepsis on survival. Department of Veterans Affairs Systemic Sepsis Cooperative Studies Group

1 reference

12 December 2020

Drotrecogin alpha (activated).

1 reference

12 December 2020

Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis

1 reference

12 December 2020

Clinical Trial Design and Outcomes in Patients with Severe Sepsis

1 reference

12 December 2020

New treatment strategies for severe sepsis and septic shock

1 reference

12 December 2020

Drotrecogin alfa (activated)

1 reference

12 December 2020

Long-term mortality and medical care charges in patients with severe sepsis

1 reference

12 December 2020

Impact of drotrecogin alfa (activated) on resource use and implications for reimbursement

1 reference

12 December 2020

Drotrecogin alfa (activated) treatment of older patients with severe sepsis.

1 reference

12 December 2020

Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis

1 reference

12 December 2020

Long-term cost effectiveness of drotrecogin alfa (activated): an unanswered question

1 reference

12 December 2020

Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients

1 reference

12 December 2020

Identifying patients with severe sepsis who should not be treated with drotrecogin alfa (activated).

1 reference

12 December 2020

Selecting patients with severe sepsis for drotrecogin alfa (activated) therapy

1 reference

12 December 2020

Economic evaluation of new therapies in critical illness

1 reference

12 December 2020

Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany

1 reference

12 December 2020

Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach

1 reference

12 December 2020

Current issues regarding the use of drotrecogin alfa (activated).

1 reference

12 December 2020

[Cost-effectiveness of drotrecogin alpha [activated] in the treatment of severe sepsis in Spain]

1 reference

12 December 2020

The influence of clinical study design on cost-effectiveness projections for the treatment of gram-negative sepsis with human anti-endotoxin antibody

1 reference

12 December 2020

1 reference

12 December 2020

Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care

1 reference

12 December 2020

Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial.

1 reference

12 December 2020

Efficacy and safety of recombinant human activated protein C for severe sepsis

1 reference

12 December 2020

New approaches to the treatment of sepsis

1 reference

12 December 2020

Innovative therapies for sepsis

1 reference

12 December 2020

Economic aspects of severe sepsis: a review of intensive care unit costs, cost of illness and cost effectiveness of therapy

1 reference

12 December 2020

Drotrecogin alfa (recombinant human activated protein C) for the treatment of severe sepsis

1 reference

12 December 2020

1 reference

12 December 2020

Activated protein C in severe sepsis

1 reference

12 December 2020

Relationship between the inflammation and coagulation pathways in patients with severe sepsis: implications for therapy with activated protein C.

1 reference

12 December 2020

An evaluation of the cost effectiveness of drotrecogin alfa (activated) relative to the number of organ system failures

1 reference

12 December 2020

Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine

1 reference

12 December 2020

Early goal-directed therapy in the treatment of severe sepsis and septic shock

1 reference

12 December 2020

The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors.

1 reference

12 December 2020

Recombinant human activated protein C, drotrecogin alfa (activated): a novel therapy for severe sepsis

1 reference

12 December 2020

Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial

1 reference

12 December 2020

Severe sepsis-national estimates

1 reference

12 December 2020

The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis

1 reference

12 December 2020

Recombinant human activated protein C (Xigris)

1 reference

12 December 2020

An economic evaluation of activated protein C treatment for severe sepsis

1 reference

12 December 2020

Clinical review: Drotrecogin alfa (activated) as adjunctive therapy for severe sepsis--practical aspects at the bedside and patient identification

1 reference

12 December 2020

Pharmacology, clinical efficacy, and safety of drotrecogin alfa (activated).

1 reference

12 December 2020

Pharmacoeconomic implications of new therapies in sepsis

1 reference

12 December 2020

Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis

1 reference

12 December 2020

Drotrecogin alfa (activated) for severe sepsis

1 reference

12 December 2020

Management challenge with drotrecogin alfa (activated).

1 reference

12 December 2020

Treatment of sepsis: past and future avenues

1 reference

12 December 2020

Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party

1 reference

12 December 2020

Hospital cost containment in the 1980s. Hard lessons learned and prospects for the 1990s

1 reference

12 December 2020

Drotrecogin alfa (activated) (recombinant human activated protein C) for the treatment of severe sepsis

1 reference

12 December 2020

Burden of illness imposed by severe sepsis in Germany.

1 reference

12 December 2020

Strategies to optimize drotrecogin alfa (activated) use: guidelines and therapeutic controversies

1 reference

12 December 2020

APACHE II: a severity of disease classification system

1 reference

12 December 2020

10.2165/00019053-200422070-00004

Identifiers

DOI

1 reference

PubMed ID

15137883

Dimensions Publication ID

10 August 2017

0 references

1 reference

PubMed ID

15137883